The known-unknown: third- and fourth-generation cephalosporins combined with sulbactam

Despite the presence of more than 100 different antibacterials in the therapeutic arsenal, beta-lactam antibiotics, in general, and the third-generation cephalosporins, in particular, remain the main option for the treatment of the most of infections in inpatients. At the same time, the widespread and oftentimes inappropriate use of the third-generation cephalosporins in Russian hospitals lead to the emergence and spread of antimicroabial resistance. The review covers the problems of antibiotic resistance to cephalosporins due to the production of beta-lactamases, the role of beta-lactamase inhibitors in overcoming this type of resistance, options for combinations of cephalosporins with beta-lactamase inhibitors, in vitro activity of cefotaxime/sulbactam and cefepime/sulbactam, the results of clinical studies, and the role of the above combinations in the treatment of infections in the hospital.

[1]  Xiaobo Huang,et al.  Sulbactam combined with tigecycline improves outcomes in patients with severe multidrug-resistant Acinetobacter baumannii pneumonia , 2022, BMC Infectious Diseases.

[2]  K. Seme,et al.  European Society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by Multidrug-resistant Gram-negative bacilli (endorsed by ESICM -European Society of intensive care Medicine). , 2021, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[3]  J. Intra,et al.  Old and New Beta-Lactamase Inhibitors: Molecular Structure, Mechanism of Action, and Clinical Use , 2021, Antibiotics.

[4]  K. A. Popugaev,et al.  Открытое, многоцентровое, наблюдательное исследование применения антибиотика цефепим/сульбактам (Максиктам ® -АФ) у пациентов с абдоминальной инфекцией или нозокомиальной пневмонией или пневмонией, ассоциированной с ИВЛ (исследование МАКСИ-2019) , 2021 .

[5]  L. Leibovici,et al.  New β-Lactam–β-Lactamase Inhibitor Combinations , 2020, Clinical Microbiology Reviews.

[6]  Bimin Feng,et al.  Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: a systematic review and network meta-analysis. , 2020, Journal of global antimicrobial resistance.

[7]  A. Kazachenko,et al.  [Prevention of infectious and inflammatory complications after percutaneous nephrolithotomy]. , 2020, Urologiia.

[8]  E. Burmistrova,et al.  Эффективность, безопасность и риск селекции резистентной микрофлоры при лечении тяжелых инфекций в стационаре препаратом с действующими веществами цефепим + [сульбактам] по сравнению с препаратами карбапенемов , 2020 .

[9]  M. Edelstein,et al.  [Current state of antibiotic resistance of pathogens causing community-acquired urinary tract infections in Russia, Belarus and Kazakhstan: results of the international multicenter study Darmis-2018]. , 2020, Urologiia.

[10]  Pia Abel zur Wiesch,et al.  Identifying the drivers of multidrug-resistant Klebsiella pneumoniae at a European level , 2019, PLoS Comput. Biol..

[11]  M. Zhuravleva,et al.  Open-label, randomised, controlled study to compare the efficacy and safety of cefepime/sulbactam and cefepime in patients with acute pyelonephritis , 2018, Clinical pharmacology and therapy.

[12]  N. Martin,et al.  β-lactam/β-lactamase inhibitor combinations: an update. , 2018, MedChemComm.

[13]  K. Bush,et al.  Past and Present Perspectives on β-Lactamases , 2018, Antimicrobial Agents and Chemotherapy.

[14]  K. Bush,et al.  β-Lactams and β-Lactamase Inhibitors: An Overview. , 2016, Cold Spring Harbor perspectives in medicine.

[15]  Kazuaki Matsumoto,et al.  Population pharmacokinetic-pharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: dosing considerations for Acinetobacter baumannii infections. , 2015, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[16]  K. Kaur,et al.  Evaluation of efficacy and tolerability of cefotaxime and sulbactam versus cefepime and tazobactam in patients of urinary tract infection-a prospective comparative study. , 2014, Journal of clinical and diagnostic research : JCDR.

[17]  C. Kumana,et al.  Clinical Role of β-Lactam/β-Lactamase Inhibitor Combinations , 2012, Drugs.

[18]  M. Kulkarni,et al.  Comparative evaluation of efficacy and safety of cefotaxime-sulbactam with amoxicillin-clavulanic acid in children with lower respiratory tract infections , 2008, Expert opinion on pharmacotherapy.

[19]  D. Maki,et al.  The Commonality of Risk Factors for Nosocomial Colonization and Infection with Antimicrobial-Resistant Staphylococcus aureus, Enterococcus, Gram-Negative Bacilli, Clostridium difficile, and Candida , 2002, Annals of Internal Medicine.

[20]  R. Kozlov,et al.  ANTIMICROBIAL RESISTANCE PATTERNS AMONG AEROBIC GRAM-NEGATIVE BACILLI ISOLATED FROM PATIENTS IN INTENSIVE CARE UNITS: RESULTS OF A MULTICENTER STUDY IN RUSSIA , 1998 .

[21]  K. Bush,et al.  Beta-lactamase inhibitors from laboratory to clinic , 1988, Clinical Microbiology Reviews.

[22]  R. Kozlov,et al.  Consumption of systemic antibiotics in the Russian Federation in 2017–2021 , 2022, Clinical Microbiology and Antimicrobial Chemotherapy.

[23]  I. Andreeva,et al.  Ceftazidimeavibactam use in children and adolescents , 2021, Clinical Microbiology and Antimicrobial Chemotherapy.

[24]  OUP accepted manuscript , 2021, Clinical Infectious Diseases.

[25]  K. Khokhlova,et al.  Antimicrobial resistance of nosocomial Enterobacterales isolates in Russia: results of multicenter epidemiological study “MARATHON 2015–2016” , 2019, Clinical Microbiology and Antimicrobial Chemotherapy.

[26]  M. Solanki,et al.  Cefoperazone + sulbactam versus cefotaxime + sulbactam combination therapy for the treatment of complicated urinary tract infections in hospitalized patients: Safety and efficacy analysis , 2019, National Journal of Physiology, Pharmacy and Pharmacology.

[27]  R. Kozlov,et al.  Ceftazidime-avibactam: new rules for the game against multidrug-resistant gram-negative bacteria , 2018 .